Skip to content
Endless Frontier LabsEndless Frontier Labs
  • About
  • Tracks
    • Deep Tech
    • Life Sciences
  • Startups
  • Mentors
  • News
Current News

A2A Pharmaceuticals Announces Collaboration With LAXAI Life Sciences to Co-develop SARS-CoV-2 Main Proteases Inhibitors for the Treatment of COVID-19

Posted on June 10, 2020November 12, 2020 by Khoa Ma
10
Jun
EFL Alum, A2A Pharmaceuticals, Announces Collaboration With LAXAI Life Sciences to Co-develop SARS-CoV-2 Main Proteases Inhibitors for the Treatment of COVID-19
This entry was posted in Current News. Bookmark the permalink.
Khoa Ma

EFL Scientific Mentor, Hanna Halaburda, Discusses Her Thoughts on the Post COVID-19 Financial Paradigm and What This Means for Digital Assets like Cryptocurrency.
C2i Genomics Raises $12M in Series A Funding
Recent Posts
  • Job Openings for Chief Data Scientist, Lead Data Scientist (Genomics, Omics, NGS, Oncology) at My Personal Therapeutics
  • Vesper Healthcare Announces Business Combination with HydraFacial
  • Job Openings for Head of Product, Lab Manager, Research Technician, Scientist, and Biochemistry (Ph.D.) at Tierra Biosciences
  • Barry J. Glick Joins Stratyfy’s Advisory Board: Technology legend brings unparalleled leadership and experience
  • Stratyfy appoints Deniz Johnson as COO: Veteran fintech executive cements foundation for future growth
Recent Comments

    ABOUT
    TRACKS
    STARTUPS
    MENTORS

    TEAM

    ELIZABETH ELTING FUND
    FAQs
    CONTACT

    NEWS

    Copyright 2021 © Endless Frontier Labs | Privacy Policy
    • About
    • Tracks
      • Deep Tech
      • Life Sciences
    • Startups
    • Mentors
    • Team
    • Elizabeth Elting Fund
    • FAQs
    • News
    • Dashboard